EX VIVO CULTURES OF INTESTINAL BIOPSIES FROM PATIENTS WITH IBD
EX VIVO CULTURES OF INTESTINAL BIOPSIES FROM PATIENTS WITH IBD ***
Ex vivo intestinal biopsy cultures from patients with IBD represent an advanced platform for preclinical drug testing, as they preserve the in vivo tissue architecture and faithfully reflect the pathological alterations of these diseases.
This methodology allows for the study of cells within their native microenvironment, maintaining the integrity of both cellular and extracellular structures for up to 24 hours after sample collection.
Tissue responses to stimuli reflect not only the activity of the drug but also cell–matrix interactions, providing results that are highly clinically relevant.
We use endoscopic biopsies from patients with IBD or colorectal cancer, as well as from healthy donors, following the signing of informed consent and approval by the competent Ethics Committee, to generate personalized intestinal biopsy cultures.
To assess the efficacy of a treatment, we offer the evaluation of the following parameters:
- RNA sequencing on tissue biopsies
- Luminex Discovery 35-plex on supernatants for quantification of inflammatory cytokines/chemokines
- Immunohistochemistry on tissue biopsies
***NOTE: All experiments conducted on human samples are carried out in accordance with Good Clinical Practice (GCP) guidelines and in compliance with all applicable international laws and regulations, as well as any relevant guidelines. Each protocol, along with the Informed Consent signed by patients, is submitted for approval to the appropriate Ethics Committee.